For research use only. Not for therapeutic Use.
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent[1][2].
| Catalog Number | I042124 |
| CAS Number | 1374419-41-6 |
| Purity | ≥95% |
| Reference | [1]. Bruno François, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018 Nov;44(11):1787-1796. [2]. Philippe Vignon, et al. New Agents in Development for Sepsis: Any Reason for Hope? Drugs. 2020 Nov;80(17):1751-1761. |
